Vinicius Fernandes Oliveira1, Graziella Ribeiro De Sousa2, Antonio Carlos Dos Santos3, Fabiano Pinto Saggioro4, Helio Rubens Machado5, Ricardo Santos de Oliveira6, Luiz Gonzaga Tone7, Elvis Terci Valera8. 1. Faculty of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil. 2. Department of Genetics, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil. 3. Department of Oncology and Image, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil. 4. Department of Pathology, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil. 5. Division of Pediatric Neurosurgery, Department of Surgery and Anatomy, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil. 6. Division of Neurosurgery, Department of Surgery and Anatomy, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil. 7. Department of Pediatrics, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Avenida Bandeirantes, 3900, Bloco G, 1 Andar, Ribeirão Preto, SP, 14049-900, Brazil. 8. Department of Pediatrics, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Avenida Bandeirantes, 3900, Bloco G, 1 Andar, Ribeirão Preto, SP, 14049-900, Brazil. etvalera@hcrp.usp.br.
Abstract
PURPOSE: Somatic mutations on H3 histone are currently considered a genetic hallmark for midline pediatric high-grade gliomas (HGGs). Yet, different tumor histologies have been occasionally described to carry these mutations. Since histone modifications can lead to major epigenetic changes with direct impact on prognosis and treatment, we thought to investigate the occurrence of H3F3A K27M and G34R/V mutations in a cohort of pediatric tumors which included HGGs, low-grade gliomas, ependymomas, medulloblastomas, and a series of rare brain tumor lesions of different histologies. METHODS: A total of 82 fresh-frozen pediatric brain tumor samples were evaluated. PCR or RT-PCR followed by Sanger sequencing for the exon 2 of H3F3A (containing both K27 and G34 hotspots) were obtained and aligned to human genome. Loss of trimethylation mark (H3K27me3) in H3F3A/K27M-mutant samples was confirmed by immunohistochemistry. RESULTS: We found H3F3A/K27M mutation in 2 out of 9 cases of HGGs; no H3F3A/K27M mutations were detected in low-grade gliomas (27), ependymomas (n = 10), medulloblastomas (n = 21), or a series of rare pediatric brain tumors which included meningiomas, dysembryoplastic neuroepithelial tumors (DNETs), central nervous system (CNS) germ-cell tumors, choroid plexus tumors, cortical hamartoma, subcortical tubers, and schwannomas (n = 15). H3F3A/G34R/V mutation was not observed in any of the samples. CONCLUSIONS: Our investigation reinforces the low frequency of H3F3A somatic mutations outside the HGG setting. Interestingly, an atypical focal brainstem glioma carrying H3F3A K27M mutation that showed protracted clinical course with late-onset tumor progression was identified.
PURPOSE: Somatic mutations on H3 histone are currently considered a genetic hallmark for midline pediatric high-grade gliomas (HGGs). Yet, different tumor histologies have been occasionally described to carry these mutations. Since histone modifications can lead to major epigenetic changes with direct impact on prognosis and treatment, we thought to investigate the occurrence of H3F3A K27M and G34R/V mutations in a cohort of pediatric tumors which included HGGs, low-grade gliomas, ependymomas, medulloblastomas, and a series of rare brain tumor lesions of different histologies. METHODS: A total of 82 fresh-frozen pediatric brain tumor samples were evaluated. PCR or RT-PCR followed by Sanger sequencing for the exon 2 of H3F3A (containing both K27 and G34 hotspots) were obtained and aligned to human genome. Loss of trimethylation mark (H3K27me3) in H3F3A/K27M-mutant samples was confirmed by immunohistochemistry. RESULTS: We found H3F3A/K27M mutation in 2 out of 9 cases of HGGs; no H3F3A/K27M mutations were detected in low-grade gliomas (27), ependymomas (n = 10), medulloblastomas (n = 21), or a series of rare pediatric brain tumors which included meningiomas, dysembryoplastic neuroepithelial tumors (DNETs), central nervous system (CNS) germ-cell tumors, choroid plexus tumors, cortical hamartoma, subcortical tubers, and schwannomas (n = 15). H3F3A/G34R/V mutation was not observed in any of the samples. CONCLUSIONS: Our investigation reinforces the low frequency of H3F3A somatic mutations outside the HGG setting. Interestingly, an atypical focal brainstem glioma carrying H3F3A K27M mutation that showed protracted clinical course with late-onset tumor progression was identified.
Authors: Jeremy Schwartzentruber; Andrey Korshunov; Xiao-Yang Liu; David T W Jones; Elke Pfaff; Karine Jacob; Dominik Sturm; Adam M Fontebasso; Dong-Anh Khuong Quang; Martje Tönjes; Volker Hovestadt; Steffen Albrecht; Marcel Kool; Andre Nantel; Carolin Konermann; Anders Lindroth; Natalie Jäger; Tobias Rausch; Marina Ryzhova; Jan O Korbel; Thomas Hielscher; Peter Hauser; Miklos Garami; Almos Klekner; Laszlo Bognar; Martin Ebinger; Martin U Schuhmann; Wolfram Scheurlen; Arnulf Pekrun; Michael C Frühwald; Wolfgang Roggendorf; Christoph Kramm; Matthias Dürken; Jeffrey Atkinson; Pierre Lepage; Alexandre Montpetit; Magdalena Zakrzewska; Krzystof Zakrzewski; Pawel P Liberski; Zhifeng Dong; Peter Siegel; Andreas E Kulozik; Marc Zapatka; Abhijit Guha; David Malkin; Jörg Felsberg; Guido Reifenberger; Andreas von Deimling; Koichi Ichimura; V Peter Collins; Hendrik Witt; Till Milde; Olaf Witt; Cindy Zhang; Pedro Castelo-Branco; Peter Lichter; Damien Faury; Uri Tabori; Christoph Plass; Jacek Majewski; Stefan M Pfister; Nada Jabado Journal: Nature Date: 2012-01-29 Impact factor: 49.962
Authors: Pooja Panwalkar; Jonathan Clark; Vijay Ramaswamy; Debra Hawes; Fusheng Yang; Christopher Dunham; Stephen Yip; Juliette Hukin; Yilun Sun; Matthew J Schipper; Lukas Chavez; Ashley Margol; Melike Pekmezci; Chan Chung; Adam Banda; Jill M Bayliss; Sarah J Curry; Mariarita Santi; Fausto J Rodriguez; Matija Snuderl; Matthias A Karajannis; Amanda M Saratsis; Craig M Horbinski; Anne-Sophie Carret; Beverly Wilson; Donna Johnston; Lucie Lafay-Cousin; Shayna Zelcer; David Eisenstat; Marianna Silva; Katrin Scheinemann; Nada Jabado; P Daniel McNeely; Marcel Kool; Stefan M Pfister; Michael D Taylor; Cynthia Hawkins; Andrey Korshunov; Alexander R Judkins; Sriram Venneti Journal: Acta Neuropathol Date: 2017-07-21 Impact factor: 17.088
Authors: Scott Ryall; Miguel Guzman; Samer K Elbabaa; Betty Luu; Stephen C Mack; Michal Zapotocky; Michael D Taylor; Cynthia Hawkins; Vijay Ramaswamy Journal: Childs Nerv Syst Date: 2017-06-16 Impact factor: 1.475
Authors: Azadeh Ebrahimi; Marco Skardelly; Martin U Schuhmann; Martin Ebinger; David Reuss; Manuela Neumann; Ghazaleh Tabatabai; Patricia Kohlhof-Meinecke; Jens Schittenhelm Journal: J Cancer Res Clin Oncol Date: 2019-01-04 Impact factor: 4.553
Authors: Michael Karremann; Gerrit H Gielen; Marion Hoffmann; Maria Wiese; Niclas Colditz; Monika Warmuth-Metz; Brigitte Bison; Alexander Claviez; Dannis G van Vuurden; André O von Bueren; Marco Gessi; Ingrid Kühnle; Volkmar H Hans; Martin Benesch; Dominik Sturm; Rolf-Dieter Kortmann; Andreas Waha; Torsten Pietsch; Christof M Kramm Journal: Neuro Oncol Date: 2018-01-10 Impact factor: 12.300
Authors: Gang Wu; Alberto Broniscer; Troy A McEachron; Charles Lu; Barbara S Paugh; Jared Becksfort; Chunxu Qu; Li Ding; Robert Huether; Matthew Parker; Junyuan Zhang; Amar Gajjar; Michael A Dyer; Charles G Mullighan; Richard J Gilbertson; Elaine R Mardis; Richard K Wilson; James R Downing; David W Ellison; Jinghui Zhang; Suzanne J Baker Journal: Nat Genet Date: 2012-01-29 Impact factor: 38.330
Authors: Débora Cabral de Carvalho Corrêa; Francine Tesser-Gamba; Indhira Dias Oliveira; Nasjla Saba da Silva; Andrea Maria Capellano; Maria Teresa de Seixas Alves; Patrícia Alessandra Dastoli; Sergio Cavalheiro; Silvia Regina Caminada de Toledo Journal: J Cancer Res Clin Oncol Date: 2021-10-09 Impact factor: 4.553